BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1713 related articles for article (PubMed ID: 24718959)

  • 1. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.
    Corbett M; Soares M; Jhuti G; Rice S; Spackman E; Sideris E; Moe-Byrne T; Fox D; Marzo-Ortega H; Kay L; Woolacott N; Palmer S
    Health Technol Assess; 2016 Feb; 20(9):1-334, v-vi. PubMed ID: 26847392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Certolizumab pegol in axial spondyloarthritis.
    Song IH; Rudwaleit M
    Expert Rev Clin Immunol; 2013 Dec; 9(12):1161-72. PubMed ID: 24215406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapies for spondyloarthritis: what is new?
    Baraliakos X; Braun J
    Curr Rheumatol Rep; 2012 Oct; 14(5):422-7. PubMed ID: 22855297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
    Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
    Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
    Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
    Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.
    Machado MA; Barbosa MM; Almeida AM; de Araújo VE; Kakehasi AM; Andrade EI; Cherchiglia ML; Acurcio Fde A
    Rheumatol Int; 2013 Sep; 33(9):2199-213. PubMed ID: 23686218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.
    Song IH; Weiß A; Hermann KG; Haibel H; Althoff CE; Poddubnyy D; Listing J; Lange E; Freundlich B; Rudwaleit M; Sieper J
    Ann Rheum Dis; 2013 Jun; 72(6):823-5. PubMed ID: 23172749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
    Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
    Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.
    Lubrano E; Perrotta FM; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Olivieri I; Punzi L; Salvarani C
    J Rheumatol; 2015 Feb; 42(2):258-63. PubMed ID: 25512483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
    Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
    Aaltonen KJ; Virkki LM; Malmivaara A; Konttinen YT; Nordström DC; Blom M
    PLoS One; 2012; 7(1):e30275. PubMed ID: 22272322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.
    Ren L; Li J; Luo R; Tang R; Zhu S; Wan L
    Am J Med Sci; 2013 Dec; 346(6):455-61. PubMed ID: 23715113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Wang S; He Q; Shuai Z
    Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
    Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.
    Dhillon S
    Drugs; 2014 Jun; 74(9):999-1016. PubMed ID: 24919863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 86.